CurrentUnitedHealthcarePolicy CS081PA.N

Nerve Graft to Restore Erectile Function During Radical Prostatectomy (for Pennsylvania Only) – Community Plan Medical Policy

Policy Summary

PayerUnitedHealthcare

PolicyNerve Graft to Restore Erectile Function During Radical Prostatectomy (for Pennsylvania Only) – Community Plan Medical Policy

Policy CodePolicy CS081PA.N

Change TypeRevised (supporting information updated)

Effective DateFeb 1, 2026

Next Review Date

Key ActionConfirm member is covered under Pennsylvania Community Plan; the policy applies only to Pennsylvania members and autologous or allogenic nerve grafting to restore erectile function is considered unproven and subject to denial.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

1States covered

0Covered Indications

2Reference CPT/unlisted codes listed

Coverage Summary & Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Policy governs coverage of autologous or allogenic nerve grafting procedures intended to restore erectile function during or after radical prostatectomy for members of UnitedHealthcare Community Plan in Pennsylvania only. This procedure (e.g., sural nerve grafting) is addressed under policy CS081PA.N effective February 1, 2026 and applies only to Pennsylvania members.

Autologous (e.g., sural) or allogenic nerve grafts to restore erectile function during or after radical prostatectomy are considered unproven and not medically necessary for Pennsylvania Community Plan members due to insufficient evidence of efficacy; the evidence base includes case series, retrospective studies, and one randomized trial terminated early for lack of benefit.

Medical Necessity Determination

Coverage determination for nerve grafting to restore erectile function during or after radical prostatectomy:

ALL of the following

State applicability: Service applies only to members in the state of Pennsylvania
Policy applicability limited to Pennsylvania
Procedure description: Autologous (e.g., sural) or allogenic nerve grafts to restore erectile function during or after radical prostatectomy
Procedure description
Coverage determination: Surgical nerve grafting to restore erectile function is considered unproven and not medically necessary due to insufficient evidence of efficacy
Coverage rationale: insufficient quality evidence

Provider Actions & Administrative Requirements

Documentation Required

State applicability

Confirm member is covered under the Pennsylvania Community Plan; the policy applies only to Pennsylvania members. Requests outside Pennsylvania will be evaluated case-by-case per Pennsylvania Exceptions.

Applies only to Pennsylvania members.

Prior Authorization

Prior authorization and benefit determination

Requests that do not meet criteria in the Pennsylvania Access and Referral Plan (PARP) will be evaluated on a case-by-case basis; verify federal, state, or contractual benefit requirements which may supersede this policy.

Denial Risk

Coverage denial for nerve grafting procedures

Autologous or allogenic nerve grafting to restore erectile function during or after radical prostatectomy is considered unproven and not medically necessary and is subject to denial.

Affected procedure codes: 55899, 64999

Background, Evidence Summary & Definitions

Nerve grafting (for example, sural nerve grafting) has been proposed to restore erectile function after radical prostatectomy when neurovascular bundles are resected; the sural nerve is commonly used as an expendable donor nerve harvested from the leg and grafted to the resected cavernous nerve.

Overall, the clinical evidence is limited and of insufficient quality to establish efficacy: available data consist primarily of single-arm case series and retrospective studies suggesting possible benefit but with substantial risk of bias, and one randomized trial that was terminated early after an interim analysis showed no increased potency with unilateral sural nerve grafting compared with control. Systematic review authors and guideline statements conclude that evidence is inadequate to support routine use and that further randomized trials with long-term follow-up are needed.

Study / Source	Key finding
Randomized trial (Davis et al. 2009)	Single‑institution randomized trial comparing unilateral sural nerve grafting (SNG) plus unilateral nerve‑sparing RP (UNS RP) versus UNS RP alone; interim analysis after 107 randomized participants showed similar potency rates at two years (44% SNG vs 43% control), trial stopped early for lack of benefit — a smaller benefit could not be excluded.
Systematic review (Shauly et al. 2019)	Systematic review identified six publications addressing cavernous nerve graft reconstruction but these were limited by lack of comparison groups and small study populations; evidence inadequate to make firm conclusions.
Recent feasibility/case series (Harke et al. 2023)	First‑in‑men feasibility series (n=6) of spider silk erectile nerve reconstruction during robotic RP found the technique safe and feasible with some participants reporting erections sufficient for penetration by three months, but nonrandomized design and small sample size preclude efficacy conclusions; randomized trials with longer follow‑up needed.

Sural nerve grafting (SNG): Autologous harvest of the sural nerve from the leg and grafting to the resected cavernous nerve during radical prostatectomy.

Radical prostatectomy (RP): Surgical removal of the prostate gland for localized prostate cancer; may involve bilateral resection of neurovascular bundles.